60 related articles for article (PubMed ID: 7044961)
1. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
[TBL] [Abstract][Full Text] [Related]
2. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
[TBL] [Abstract][Full Text] [Related]
3. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
4. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide.
Xu Z; Fidler IJ
Cancer Immunol Immunother; 1984; 18(2):118-22. PubMed ID: 6391654
[TBL] [Abstract][Full Text] [Related]
5. New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV).
Zhao N; Ma Y; Zhang S; Fang X; Liang Z; Liu G
Bioorg Med Chem Lett; 2011 Jul; 21(14):4292-5. PubMed ID: 21683593
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of Nucleotide Oligomerization Domain and Toll-Like Receptors 2 to Enhance the Effect of Bacillus Calmette Guerin Immunization for Prevention of Mycobacterium Tuberculosis Infection: Protocol for a Series of Preclinical Randomized Controlled Trials.
Eisenhut M
JMIR Res Protoc; 2019 Jun; 8(6):e13045. PubMed ID: 31199313
[TBL] [Abstract][Full Text] [Related]
7. Role of the major histocompatibility complex in resistance and granuloma formation in response to Mycobacterium lepraemurium infection.
Adu HO; Curtis J; Turk JL
Infect Immun; 1983 May; 40(2):720-5. PubMed ID: 6220974
[TBL] [Abstract][Full Text] [Related]
8. Microbicidal activity and morphological characteristics of lung macrophages in Mycobacterium bovis BCG cell wall-induced lung granuloma in mice.
Kato K; Yamamoto K; Okuyama H; Kimura T
Infect Immun; 1984 Aug; 45(2):325-31. PubMed ID: 6086525
[TBL] [Abstract][Full Text] [Related]
9. [Epithelioid cell granuloma (author's transl)].
Okabe M; Okuyama H; Morikawa K
Kekkaku; 1980 Oct; 55(10):435-42. PubMed ID: 7014971
[No Abstract] [Full Text] [Related]
10. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
Chedid L; Carelli C; Audibert F
J Reticuloendothel Soc; 1979 Dec; 26(Suppl):631-41. PubMed ID: 392087
[No Abstract] [Full Text] [Related]
11. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
[TBL] [Abstract][Full Text] [Related]
12. Relationship of anti-tuberculous protection to lung granuloma produced by intravenous injection of synthetic 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kakinuma M; Kato K; Okuyama H; Azuma I
Immunology; 1980 Aug; 40(4):557-64. PubMed ID: 7000685
[TBL] [Abstract][Full Text] [Related]
13. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
14. Failure of C3H mice to develop lung granuloma after intravenous injection of BCG cell wall vaccine. Demonstration of a defect in lymphoid cells.
Kakinuma M; Onoé K; Okada M; Kimura T; Kato K; Okuyama H; Morikawa K; Yamamoto K
Immunology; 1981 May; 43(1):1-9. PubMed ID: 6972900
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response.
Lowy I; Theze J; Chedid L
J Immunol; 1980 Jan; 124(1):100-4. PubMed ID: 6965289
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
